Navigation Links
DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv
Date:2/9/2010

to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

RELATED LINKS
http://www.datatrak.net

'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DATATRAK Attends 13th Annual DIA Workshop in Japan for Clinical Data Management
2. DATATRAK International, Inc. Announces Year-End Backlog
3. DATATRAK Signs Five-Year Registry Study
4. DATATRAKs eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM)
5. PFC Pharma Joins DATATRAKs CRO Connect Program
6. DATATRAK Signs 6 Year Study with New Device Client
7. DATATRAK to Present at 2009 SCDM Annual Conference
8. DATATRAK eClinical(TM) Supports Multifaceted Studies
9. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
10. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
11. DATATRAK International Reports First Quarter Results for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:6/29/2015)... ... , ... USA Today reported on June 18th the overdose death ... impact the rest of the nation’s growing overdose death rates in 26 other states ... followed to stop the increasing overdose trend from continuing: , , ...
(Date:6/29/2015)... ... , ... OR Manager announced Monday the launch of an enhanced http://www.ormanager.com ... redesigned logo and weekly eLetter. The website contains the same informational articles, products, and ... navigate. , In addition to a refreshed look, http://www.ormanager.com now provides ...
(Date:6/29/2015)... ... June 29, 2015 , ... New research ... fewer than 10 percent of U.S. state and local governments have implemented Next ... implementation deadline for NG9-1-1. , “Mobile phones have surpassed land lines as ...
(Date:6/29/2015)... ... 2015 , ... The Food Safety and Technology Research Centre ... Polytechnic University (PolyU) has developed a new method for rapid authentication of edible ... long-term issue in food safety, and becomes particularly important with the emergence and ...
(Date:6/29/2015)... ... , ... FACE is proud to be one of the first in the ... chin and redefining of the jawline. Excess fat under the chin and around ... the person distress and poor self-image. , Kybella was produced by KYTHRA Biopharmaceutical and ...
Breaking Medicine News(10 mins):Health News:Overdose Death Rates Decreased in Florida as of 2015 2Health News:Overdose Death Rates Decreased in Florida as of 2015 3Health News:OR Manager Launches New Website 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 4Health News:PolyU develops a new method for rapid authentication of edible oils and screening of gutter oils 2Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2
... DHR ) commented today on the performance outlook of ... Culp, Jr. communicated the company expects 2009 earnings per share to ... , Mr. Culp stated, "We have taken significant ... a difficult year ahead. However, despite the current economic backdrop, we ...
... Study says high-altitude cerebral edema is a common problem ... Most deaths on Mount Everest occur during descents from ... meters, and high-altitude cerebral edema appears to be associated ... conclusion of researchers who analyzed the reported 212 deaths ...
... ROCK, Ark., Dec. 11 Travel Nurse across ... for healthcare staffing,services from The Joint Commission. , ... across America, a national supplemental healthcare staffing,firm, recently ... with,national standards addressing how staffing firms determine the ...
... eligible voters cast ballots in statewide election while caregivers file ... LOS ANGELES, Dec. 11 In a statewide vote of ... ballots are still being counted but the result is clear: ... union officials, and lawmakers and healthcare advocates are joining them ...
... of Tourette Syndrome , , ... last Sunday night,s Hallmark Hall of Fame presentation of "Front ... story of a young man,s struggles with and triumph over ... The national Tourette Syndrome Association, Inc. (TSA) is privileged to ...
... used to prep for colonoscopy, may harm the kidneys, ... THURSDAY, Dec. 11 (HealthDay News) -- Two prescription drugs ... cause kidney damage, the U.S. Food and Drug Administration ... require a black-box warning on the oral sodium phosphate ...
Cached Medicine News:Health News:Danaher CEO Comments on Outlook 2Health News:Most Mt. Everest Deaths Occur Near Summit During Descent 2Health News:Travel Nurse Across America Awarded Certification From The Joint Commission 2Health News:Boycott Prevails in Sham SEIU Vote; Lawmakers and Advocates Join Healthcare Workers in Opposing Forced Union Merger 2Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:FDA Puts Black-Box Warning on Bowel-Cleansing Drugs 2Health News:FDA Puts Black-Box Warning on Bowel-Cleansing Drugs 3
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: